A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 100+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №17 · week of Oct 25, 2026See the trends →
Top journals this week: Lancet / JAMA / Nature Medicine / Lancet GH
Selectivity
11.6%
16 in the issue of 138 screened
in the issue 16in depth 30held 6filtered out 86
88.4% of what published this week did not make the issue. That filter is the product. A further 30 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 10 of the 16 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. From issue 14, every match is independently re-checked, so this bar reads lower than in earlier issues. Click a segment to filter the issue.
The signal map
647891narrative reviewguideline →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version
Your subspecialty, the takeaways
IBD11Hepatology12Esophagus/Reflux2Pancreas/Biliary6Endoscopy8Colorectal4Nutrition3
Type

This week to know

the 5 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
Colorectal rct · n=400 · Oct 24, 2026 · Lancet · IF 98.4

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

New evidencecolorectal cancer
Clinical takeawayConsider the 14-day trifluridine-tipiracil plus bevacizumab schedule for refractory metastatic colorectal cancer to reduce toxicity, including neutropenia, while maintaining survival outcomes compared to the 28-day schedule.
What it foundThe 14-day trifluridine-tipiracil plus bevacizumab schedule showed non-inferior overall survival (HR 0.93, 95% CI 0.80-1.08) compared to the 28-day schedule, with median survival of 11.3 vs 10.3 months.
ContextThis confirms the 14-day schedule as a viable alternative to the conventional 28-day regimen, addressing toxicity concerns without compromising survival.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sakakida T … PRABITAS investigators · The Lancet · IF 98.4 · PubMed ↗Permalink
IBD guideline · Oct 19, 2026 · Lancet GH · IF 39.1

Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.

Guideline / reviewguidelinesystematic reviewpediatricbiologics
Clinical takeawayUse STRIDE-III targets to guide treatment decisions in IBD: prioritise actionable targets for treatment change, adjunctive targets for optimisation/monitoring, and patient-centred targets for shared decision-making. Consider specific times to target achievement and faecal calprotectin thresholds, and adapt for resource-limited settings.
What it foundSTRIDE-III defines three categories of treatment targets: actionable (clinical response/remission, CRP normalisation, faecal calprotectin within target range, endoscopic remission), adjunctive (histological/transmural remission, growth), and patient-centred (disability, fatigue, quality of life). Targets are further classified as immediate, short-term, intermediate, and long-term, with specific times to target achievement and new faecal calprotectin thresholds. Adaptations for resource-limited settings are also defined.
ContextRefines STRIDE-II by categorising targets into actionable, adjunctive, and patient-centred, with specific times to target achievement, new faecal calprotectin thresholds, and adaptations for resource-limited settings.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Decision at staketreat to target in ulcerative colitis

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Turner D … Dignass A · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗Permalink
Hepatology prospective cohort · n=3,600,000 · Oct 20, 2026 · Ann Intern Med · IF 19.6

Projected Effect of 2026 Federal Changes to the Childhood Immunization Schedule on Chronic Hepatitis B Virus Infections in the United States.

New evidenceviral hepatitispediatricepidemiologyhealth services
Clinical takeawayAdvocate for universal birth-dose HBV vaccination in infants to prevent chronic HBV infections and reduce susceptibility.
What it foundShared decision-making vaccination strategy increases childhood chronic HBV infections by 83% (467 vs 255) compared to universal birth-dose vaccination.
ContextChallenges the proposed shared decision-making strategy, confirming the superiority of universal birth-dose vaccination in preventing chronic HBV infections.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mohareb AM … Hyle EP · Annals of Internal Medicine · IF 19.6 · PubMed ↗Permalink
Hepatology guideline · Oct 22, 2026 · Hepatology · IF 18.0

AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis.

Guideline / reviewPBCguidelineliver transplant
Clinical takeawayUse UDCA first line, PPAR agonists for inadequate response or intolerance, liver stiffness measurement for prognostication, linerixibat for moderate to severe pruritus, and UDCA after transplant to reduce recurrence; certainty across the 6 recommendations ranged from moderate to very low.
What it foundThe guideline provides 6 recommendations, including UDCA as first-line therapy, liver stiffness measurement for prognostication, and linerixibat for moderate to severe pruritus.
ContextThis guideline refines current practice by providing evidence-based recommendations for diagnosis, treatment escalation, symptom management, and post-transplant care in adults with PBC.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

Decision at stakethe use of UDCA as first-line therapy for PBC

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. … If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. … After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
Levy C … Davitkov P · Hepatology · IF 18.0 · PubMed ↗Permalink
Nutrition review · Oct 21, 2026 · JAMA · IF 63.1

Obesity in Children Aged 2 to 12 Years: A Review.

Guideline / reviewpediatricepidemiologyobesityguideline
Clinical takeawayScreen children aged 2 to 12 years for obesity using BMI and offer intensive health behavior and lifestyle treatment, consisting of at least 26 contact hours of face-to-face group or family-based activities that incorporate nutrition, physical activity, and behavior change education delivered to the child and caregivers over a 3- to 12-month period.
What it foundIntensive health behavior and lifestyle treatment reduces BMI by 0.7 compared with children who do not participate in intensive health behavior and lifestyle treatment.
ContextConfirms current guidelines recommending BMI screening starting at age 2 and supports intensive lifestyle interventions as the primary treatment for childhood obesity in children aged 2 to 12 years.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Fox CK … Kelly AS · JAMA · IF 63.1 · PubMed ↗Permalink

The read

the next 11, in full

IBD· 2

IBD prospective cohort · n=234 · Oct 22, 2026 · Clin Gastro Hep · IF 16.2

Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study.

New evidenceCrohn's diseaseulcerative colitisbiologicstherapeutic drug monitoring
Clinical takeawayConsider guselkumab as a treatment option for patients with moderately-to-severely active Crohn's disease or ulcerative colitis, given its high remission rates and favorable safety profile in real-world settings, but note that 6.4% experienced adverse events, with 7 patients discontinuing treatment.
What it foundWeek 12 clinical remission was achieved in 76.8% of patients with CD (HBI<5) and 80.7% of patients with UC (SCCAI≤2), with remission maintained at 6 months in 88.4% of CD and 85.4% of UC patients.
ContextConfirms the efficacy and safety of guselkumab observed in pivotal trials, providing real-world evidence supporting its use in IBD, with a comparator of standard of care.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

… Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. … Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. … Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Shafrir A … Rubin DT · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD rct · n=386 · Oct 21, 2026 · J Gastro Hep · IF 3.5

Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials.

New evidenceulcerative colitisbiologicstherapeutic drug monitoring
Clinical takeawayConsider risankizumab as a treatment option for moderately to severely active ulcerative colitis in East Asian patients, particularly those who respond to induction therapy, based on its superior efficacy vs placebo and a safety profile consistent with global trials.
What it foundRisankizumab achieved clinical remission in 21.7% vs 5.8% at induction Week 12 and 36.9% (180 mg) vs 58.0% (360 mg) vs 26.7% (placebo withdrawal) at maintenance Week 52 in East Asian patients with ulcerative colitis.
ContextThis post hoc analysis confirms risankizumab's efficacy and safety in East Asian populations, aligning with global phase 3 trial results.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

… Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Takeuchi K … Hisamatsu T · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink

Hepatology· 3

Hepatology prospective cohort · n=598 · Oct 22, 2026 · Hepatology · IF 18.0

Baveno VI criteria validation and development of a new non-invasive strategy for varices rule-out in patients with HCC (SAPHE-R: Stiffness, ALBI, Platelets, HEpatocellular carcinoma Rule).

New evidencecirrhosisportal hypertensionhepatocellular carcinomavariceal bleeding
Clinical takeawayConsider using SAPHE-R to rule out varices in patients with HCC and compensated advanced chronic liver disease, avoiding unnecessary endoscopy in those meeting SAPHE-R criteria.
What it foundSAPHE-R (LSM≤16 kPa, platelet count ≥160×10⁹/L, ALBI grade 1) missed 4.0% of varices and 3.0% of high-risk varices, sparing 17.6% of UGE, compared to Baveno VI criteria which missed 8.5% of varices and 6.0% of HRV.
ContextChallenges Baveno VI criteria in HCC patients with compensated advanced chronic liver disease, offering a more reliable non-invasive alternative for variceal risk assessment in this population.
Refinessuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.

Decision at stakenon-invasive rule-out of varices in patients with HCC and cACLD

… Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.

American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211. · reviewed 2026-07-23 ↗
Argiento L … Italian Liver Cancer (ITA.LI.CA) consortium · Hepatology · IF 18.0 · PubMed ↗Permalink
Hepatology prospective cohort · n=1,275 · Oct 21, 2026 · Clin Gastro Hep · IF 16.2

Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates.

New evidenceliver transplant
Clinical takeawayAn LFI change of 0.4 is a candidate minimal clinically important difference for frailty programmes; this cohort cannot show that prehabilitation itself lowers mortality, and 6MWT gains did not track survival.
What it foundLiver frailty index (LFI) improvement by at least 0.4 was associated with a ∼50% reduction in mortality (HR=0.56, p=0.037).
ContextThis study provides evidence supporting the use of prehabilitation to improve frailty metrics and survival in liver transplant candidates, refining prior evidence on frailty interventions. The findings apply specifically to LT candidates with a median age of 57 and MELD score of 14.
Emergingsuggested applicable standard· AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Refer patients with decompensated cirrhosis (including those with MELD-Na <15 or MELD 3.0 <15 if they have clinically significant portal hypertension, recurrent ascites, hepatic encephalopathy, or variceal bleeding), acute liver failure meeting King's College Criteria/UNOS Status 1A, or HCC within Milan/UCSF criteria for comprehensive multidisciplinary liver transplant evaluation, with MELD 3.0 driving UNOS waitlist allocation and MELD exception scoring for HCC/HPS/FAP. Optimize modifiable risk factors before listing (alcohol abstinence, HCV DAA treatment, vaccinations, DM/obesity/OSA and dental clearance) and use bridging/downstaging locoregional therapy for HCC while awaiting transplant. After transplant, maintain lifelong immunosuppression with tacrolimus plus mycophenolate ± tapered steroids alongside infection prophylaxis and recurrent-disease surveillance.

AASLD/AST, 'AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation' (Dove L et al., Hepatology 2026;83(6):1609-1645). DOI 10.1097/HEP.0000000000001644, PMID 41405234. · reviewed 2026-07-21 ↗
Lin FP … Duarte-Rojo A · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology prospective cohort · n=8,034 · Oct 22, 2026 · J Clin Gastro · IF 2.9

High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity.

EpidemiologyepidemiologyMASLDhealth servicesbiomarker
Clinical takeawayAsking MASLD patients about fatigue, itch and sleep is reasonable; the registry documents the burden, not that screening or any treatment improves it.
What it found25% of MASLD patients reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, with fatigue independently predicting impaired HRQL and work productivity loss.
ContextConfirms and quantifies the high burden of fatigue, pruritus, and sleep disorders in MASLD, previously suspected but not systematically documented in a large global cohort. Multivariate analyses showed pruritus and sleep disorders independently predict fatigue.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Younossi ZM … Global NASH/MASH Council · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink

Esophagus/Reflux· 1

Esophagus/Reflux prospective cohort · n=9,115 · Oct 20, 2026 · Aliment Pharm Ther · IF 6.7

Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population-Based Cohort Study.

New evidenceeosinophilic esophagitisesophageal cancerepidemiologyBarrett's esophagus
Clinical takeawayThe data do not point to cancer surveillance for EoE itself: the authors conclude the oesophageal cancer association is likely mediated largely through Barrett's oesophagus, and the first-year excess sits in the diagnostic window.
What it foundAmong 9115 Danish EoE patients, GI cancer SIR was 2.83 (2.10-3.74) in the first year and 1.03 (0.85-1.23) beyond it; oesophageal cancer stayed elevated beyond 1 year (SIR 2.40, 1.42-3.79), and most of those 18 cancers occurred in patients with prior Barrett's oesophagus (SIR 5.44 with EoE plus Barrett's, 4.84 with Barrett's alone).
ContextPopulation registry cohort; the SIR for EoE without Barrett's could not be reported because cancers were too few, and the hepatocellular carcinoma estimate (2.05, 0.98-3.77) crossed 1.
Measured against the standard of care· ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

ACG 2025 (GRADE) is still the governing guideline. The ASGE 2026 consensus Part 2 (modified Delphi, 28 statements at ≥80% agreement; not GRADE) adds endoscopic and pediatric detail without contradicting it. DIAGNOSIS: symptoms of esophageal dysfunction plus ≥15 eos/hpf after excluding other causes of esophageal eosinophilia. A PPI trial is not a diagnostic criterion (PPI-REE abandoned). Do the initial diagnostic EGD off PPI, topical steroid and dietary therapy (ACG key concept; ASGE consensus, which gives no washout duration). Initial assessment is a standard EGD, not a less-invasive modality, so that full biopsies and dilation are possible (ASGE). Take ≥6 esophageal biopsies from ≥2 levels in anyone with symptoms or endoscopic findings consistent with EoE, targeting visible lesions. In CHILDREN with suspected EoE, also biopsy the stomach and duodenum (ASGE). Use EREFS at every endoscopy and report a quantified peak eosinophil count (ACG strong/low; ASGE). TREATMENT (ACG): swallowed topical steroids STRONG/moderate; high-dose PPI CONDITIONAL/low; empiric elimination diet CONDITIONAL/low. Choose a single initial therapy by shared decision-making. Fluticasone or budesonide are both reasonable. Adult doses: PPI double the reflux dose (e.g., omeprazole 20 mg BID or 40 mg daily); budesonide 2-4 mg/day (BOS 2 mg BID); fluticasone 1,760 mcg/day divided. Pediatric doses: PPI 2 mg/kg/day; budesonide 1-2 mg/day; fluticasone 110-880 mcg/day. Allergy testing is not used to direct diets. A 1FED/2FED step-up diet with a dietitian is acceptable, with endoscopic and biopsy confirmation after each reintroduced food. Dupilumab is CONDITIONAL for PPI-nonresponsive patients aged ≥12 (moderate) and for ages 1-11 at ≥15 kg (low). Weight-band dosing: 15-<30 kg 200 mg q2w; 30-<40 kg 300 mg q2w; ≥40 kg 300 mg weekly. Recommendations AGAINST: omalizumab, cromolyn, montelukast. No recommendation for cendakimab, benralizumab, lirentelimab, mepolizumab or reslizumab. DILATION: an adjunct to anti-inflammatory therapy for strictures causing dysphagia (ACG conditional/low). Start low and go slow; target ≥16 mm in adults and adolescents over ≥1 session. In children, ASGE supports dilation of symptomatic strictures or a narrow-caliber esophagus regardless of disease activity, using the same start-low/go-slow approach. MAINTENANCE: continue effective therapy (ACG STRONG despite low evidence) at the lowest effective dose. MONITORING: judge response on symptoms, endoscopy and histology together, never symptoms alone. Assess response endoscopically at 8-12 weeks after starting a PPI or topical steroid. For diet, ACG says 8-12 weeks and ASGE says 6-8 weeks. For dupilumab or biologics, assess at 12-24 weeks (ASGE: up to 24 weeks). Allow appropriate washout or timing after any treatment change before the follow-up EGD (ASGE). Take monitoring biopsies from the most severe-appearing lesions (rings, furrows, exudates) (ASGE). Monitoring biopsies may be limited to the esophagus when prior gastric and duodenal biopsies were normal and nothing new suggests other pathology (ASGE). The histologic response threshold of <15 eos/hpf is a 'may consider' target, read alongside endoscopic and symptom findings. Shorten follow-up after complications. Care gaps of ≥2 years are associated with fibrostenosis. PEDIATRIC (ACG): esophagram for children with dysphagia to assess fibrostenotic disease; feeding therapy and dietitian for feeding dysfunction; growth, development and nutrition are treatment goals.

ACG 2025 (Dellon et al., Am J Gastroenterol 120(1):31-59) / ASGE 2026 consensus Part 2 (Dellon et al., Gastrointest Endosc 103(3):396-417) · reviewed 2026-10-11 ↗
Kurt G … Sørensen HT · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink

Endoscopy· 5

Endoscopy prospective cohort · n=789 · Oct 20, 2026 · Eur J Gastro Hep · IF 2.2

Endoscopic retrograde cholangiopancreatography-related pancreatitis and cholangitis differ according to biliary stricture anatomy: a cohort study.

New evidenceERCPbiliary stricture
What it foundMiddle/high biliary strictures had higher rates of PEP (5% vs 1%) and cholangitis (4.7% vs 1.2%) compared to low strictures.
ContextThis literature reports that biliary stricture anatomy influences the risk of post-ERCP pancreatitis and cholangitis.
Emergingsuggested applicable standard· American Society for Gastrointestinal Endoscopy (ASGE), 'American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations' (Buxbaum JL et al., Gastrointest Endosc 2023;97(2):153-162). DOI 10.1016/j.gie.2022.10.005, PMID 36517310.

… Post-procedure, monitor for the major complications (pancreatitis, sphincterotomy bleeding, perforation, cholangitis) and manage by type, PEP by Cotton criteria with fluids/analgesia, bleeding with repeat endoscopic hemostasis, perforation by Stapfer classification with surgical consult for Type I, and cholangitis with empiric antibiotics (Tokyo Guidelines TG18) plus biliary drainage; these complication-management elements are unchanged from ESGE 2020.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For ALL patients undergoing ERCP (average-risk and high-risk alike), give periprocedural rectal NSAID prophylaxis (100 mg indomethacin or diclofenac) unless contraindicated (e.g., recent PUD, renal insufficiency), this is now a strong recommendation for unselected patients, not just high-risk ones. For high-risk patients undergoing repeated or deep pancreatic-duct access or ampullectomy, add a prophylactic small-caliber pancreatic duct stent (3-5Fr, preferably 5Fr, 3-7cm, removed within 5-10 days), strong recommendation; for other high-risk scenarios (difficult cannulation, prior PEP, precut sphincterotomy without fistulotomy), PD stenting is a conditional recommendation when PD access is easily achieved. Aggressive periprocedural/postprocedural IV hydration with lactated Ringer's (20 mL/kg bolus, then 3 mL/kg/h for 8h) is a conditional suggestion for unselected patients (most practical for inpatients), and wire-guided cannulation is conditionally favored over contrast-guided to reduce PEP risk. The SVI trial (Elmunzer, Lancet 2024) found rectal indomethacin alone did NOT meet non-inferiority versus indomethacin+stent in high-risk patients (PEP 14.9% vs 11.3%), supporting continued use of the combination bundle in high-risk cases rather than dropping the stent. Post-procedure, monitor for the major complications (pancreatitis, sphincterotomy bleeding, perforation, cholangitis) and manage by type, PEP by Cotton criteria with fluids/analgesia, bleeding with repeat endoscopic hemostasis, perforation by Stapfer classification with surgical consult for Type I, and cholangitis with empiric antibiotics (Tokyo Guidelines TG18) plus biliary drainage; these complication-management elements are unchanged from ESGE 2020.

American Society for Gastrointestinal Endoscopy (ASGE), 'American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations' (Buxbaum JL et al., Gastrointest Endosc 2023;97(2):153-162). DOI 10.1016/j.gie.2022.10.005, PMID 36517310. · reviewed 2026-07-21 ↗
Voulgaris T … Vezakis A · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink
Endoscopy rct · n=216 · Oct 22, 2026 · Endoscopy · IF 11.8

Cold versus hot snare endoscopic mucosal resection for 10-19-mm nonpedunculated colorectal polyps: a multicenter randomized trial.

New evidencepolypectomyEMRendoscopy qualitycolorectal cancer screening
Clinical takeawayCold snare EMR is a reasonable option for 10-14 mm nonpedunculated polyps; noninferiority was not shown for 15-19 mm lesions (78.6% vs 90.9%). Expect more intraprocedural bleeding with cold snare overall (19.1% vs 3.4%), with delayed bleeding rare.
What it foundCS-EMR achieved 90.4% complete resection vs. 93.2% for HS-EMR (difference -2.7%, 95%CI -9.8 to 4.3), meeting noninferiority within a 10% margin.
ContextConfirms CS-EMR as a viable option for 10-19-mm nonpedunculated colorectal polyps, refining prior evidence by demonstrating noninferiority in a randomized trial.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Jiang Q … Wu D · Endoscopy · IF 11.8 · PubMed ↗Permalink
Endoscopy prospective cohort · n=45 · Oct 23, 2026 · J Gastro Hep · IF 3.5

Endoscopic Ultrasound-Guided Fine-Needle Biopsy for Tissue Sampling of Biliary Strictures: A Multicenter Prospective Study.

New evidencebiliary strictureEUSendoscopy quality
Clinical takeawayConsider EUS-guided FNB with an end-cutting needle for distal biliary strictures without a mass; in peri-hilar strictures sensitivity was lower (75%) and two passes gave adequate tissue in only 60%.
What it foundEUS-guided FNB with end-cutting needles achieved 93.3% sample adequacy and 91.1% diagnostic accuracy in biliary strictures without an associated pancreatic or abdominal mass, with 96.6% adequacy in distal vs. 86.6% in peri-hilar strictures. Minor bleeding occurred in 4.4% of cases.
ContextConfirms EUS-guided FNB with end-cutting needles as a viable alternative to traditional sampling methods, with higher adequacy and accuracy rates in biliary strictures without an associated pancreatic or abdominal mass.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

… For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Facciorusso A … Crinò SF · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
Endoscopy meta analysis · n=346 · Oct 19, 2026 · GIE · IF 8.0

Meta-analysis of single session versus two-stage endoscopic ultrasound directed transgastric ERCP (EDGE) in gastric bypass patients.

New evidenceERCPEUSbariatric endoscopymeta-analysis
Clinical takeawayEither approach remains reasonable; 7 observational studies (346 patients) are too imprecise to show the two are equivalent (technical success OR 0.34, 95% CI 0.03-3.53).
What it foundSingle-session EDGE and two-stage EDGE had similar outcomes for technical success (OR 0.34, 95% CI 0.03 to 3.53), clinical success (OR 1.88, 95% CI 0.38 to 9.17), and adverse events (OR 1.45, 95% CI 0.38 to 5.48).
ContextThis meta-analysis found no significant differences in outcomes between single-session EDGE and two-stage EDGE in gastric bypass patients, suggesting comparable efficacy and safety.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Singh S … Adler DG · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy prospective cohort · n=19 · Oct 21, 2026 · Endoscopy · IF 11.8

Reconstructive Endoscopic Suturing for Defect Closure After Large ≥90% Circumferential Colorectal Endoscopic Submucosal Dissection.

New evidenceESDcolorectal cancerendoscopy qualityhemostasis
Clinical takeawayA promising signal for expert ESD centres, not yet a standard: the 0/19 vs 8/15 stricture comparison is non-randomized and the non-sutured lesions were larger; the authors call for prospective multicentre validation.
What it foundReconstructive endoscopic suturing prevented symptomatic strictures in 0/19 sutured patients versus 8/15 (53.3%) non-sutured patients with large ≥90% circumferential colorectal ESD lesions.
ContextChallenges current practice: no established prophylactic strategy exists for stricture prevention in an exceptionally high-risk cohort of colorectal ESD lesions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Aslan F … Hatipoglu A · Endoscopy · IF 11.8 · PubMed ↗Permalink
Everything else this week30 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

Also screened this week29 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

Endoscopy· 12

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.